Praxis Precision Medicines Inc [PRAX] stock is trading at $297.02, down -2.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PRAX shares have gain 5.93% over the last week, with a monthly amount glided 51.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Praxis Precision Medicines Inc [NASDAQ: PRAX] stock has seen the most recent analyst activity on December 15, 2025, when Oppenheimer reiterated its Outperform rating and also boosted its price target to $750 from $250. Previously, BTIG Research started tracking the stock with Buy rating on November 19, 2025, and set its price target to $424. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $80 on May 07, 2025. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $105 on March 03, 2025. Deutsche Bank started tracking with a Buy rating for this stock on February 11, 2025, and assigned it a price target of $111. In a note dated August 05, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $134 on this stock.
Praxis Precision Medicines Inc [PRAX] stock has fluctuated between $26.70 and $317.72 over the past year. Currently, Wall Street analysts expect the stock to reach $490.33 within the next 12 months. Praxis Precision Medicines Inc [NASDAQ: PRAX] shares were valued at $297.02 at the most recent close of the market. An investor can expect a potential return of 65.08% based on the average PRAX price forecast.
Analyzing the PRAX fundamentals
Praxis Precision Medicines Inc [NASDAQ:PRAX] reported sales of 7.46M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -34.98%, Pretax Profit Margin comes in at -32.33%, and Net Profit Margin reading is -32.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.6 and Total Capital is -0.67. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 286.82 points at the first support level, and at 276.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 306.36, and for the 2nd resistance point, it is at 315.69.
Ratios To Look Out For
For context, Praxis Precision Medicines Inc’s Current Ratio is 5.18. Further, the Quick Ratio stands at 5.18, while the Cash Ratio is 3.24. Considering the valuation of this stock, the price to sales ratio is 995.66, the price to book ratio is 18.30.
Transactions by insiders
Recent insider trading involved Nemiroff Alex, General Counsel and Secretary, that happened on Nov 20 ’25 when 25130.0 shares were sold. Principal Accounting Officer, Mastrocola Lauren completed a deal on Nov 20 ’25 to sell 13600.0 shares. Meanwhile, Officer Nemiroff Alex bought 25130.0 shares on Nov 20 ’25.
